4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% – Time to Buy?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price was up 6.2% during trading on Monday . The company traded as high as $9.54 and last traded at $9.58. Approximately 278,901 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 751,524 shares. The stock had previously closed at $9.02.

Wall Street Analyst Weigh In

FDMT has been the topic of several recent research reports. Barclays assumed coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a report on Wednesday, January 7th. Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.25.

4D Molecular Therapeutics Stock Performance

The firm has a market capitalization of $553.02 million, a P/E ratio of -2.58 and a beta of 3.01. The stock’s 50 day simple moving average is $8.47 and its 200 day simple moving average is $8.79.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at $39,000. Wexford Capital LP bought a new position in 4D Molecular Therapeutics during the 3rd quarter worth about $41,000. Los Angeles Capital Management LLC purchased a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $42,000. Quadrature Capital Ltd purchased a new position in 4D Molecular Therapeutics during the 2nd quarter valued at about $42,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.